Headaches: News on pathophysiology and treatment of migraine;Kopfschmerzen: Neues zu pathophysiologie und therapie der migräne

Notfall Medizin

Volumn 29, Issue 1-2, 2003, Pages 32-41

  Limmroth, Volker ^a   Diener, H C ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; AMPA RECEPTOR ANTAGONIST; ANTIEMETIC AGENT; ANTIMIGRAINE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL FUMARATE; CALCITONIN GENE RELATED PEPTIDE; DIHYDROERGOTAMINE; DIHYDROERGOTAMINE MESILATE; DISPATIM; DOMPERIDONE; ELETRIPTAN; ERGOSANOL; ERGOTAMINE DERIVATIVE; ERGOTAMINE TARTRATE; FLUNARIZINE; FROVATRIPTAN; IBUPROFEN; LAMOTRIGINE; LISURIDE; LISURIDE MALEATE; LYSINE ACETYLSALICYLATE; METHYSERGIDE; METHYSERGIDE MALEATE; METOCLOPRAMIDE; METOPROLOL; METOPROLOL TARTRATE; NADOLOL; NAPROXEN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIZOTIFEN; PROPRANOLOL; RIZATRIPTAN; SUBSTANCE P ANTAGONIST; SUMATRIPTAN SUCCINATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; ZOLMITRIPTAN;

DIAGNOSTIC IMAGING; DRUG EFFECT; DRUG EFFICACY; ERGOKRANIT; GENETICS; HEADACHE; HUMAN; MIGRAINE; MIGREXA; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; PROPHYLAXIS; REVIEW; TREATMENT PLANNING;

EID: 0041692535     PISSN: 03412903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Bahra A, Matharu M, Büchel C, and Frakowiak RSJ. Brainstem activation specific to migraine headache. Lancet 2001; 357: 1016-7
2. Behan PO and Connelly K. Prophylaxis of migraine: a comparison between naproxen sodium and pizotifen. Headache 1986; 26, 237-239
3. Bellavance AJ and Meloche JP. Comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis. Headache 1990; 30, 710-715
4. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002; 8: 136-42
5. Brown EG, Endersby CA, Smith RN, Talbot JCC. The safety and tolerability of sumatriptan: an overview. Eur Neurol 1991; 31, 339-344
6. Buring JE, Peto R, and Hennekens CH. Low-dose aspirin for migraine prophylaxis. JAMA 1990; 264, 1711-1713
7. Caekebeke JF, Ferrari MD, Zwetsloot CP, Jansen J, Saxena PR. Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks. Neurology 1992; 42: 1522-6
8. Cutrer FM, Sorensen AG, Weisskoff RM, Ostergaard L, Sanchez del Rio M, Lee EJ, Rosen BR, Moskowitz MA. Perfusion-weighted imaging defects during spontaneous migrainous aura. Ann Neurol 1998; 43: 25-31
9. D'Andrea G, Granella F, Cadaldini M, Manzoni GC. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia 1999; 19: 64-6
10. Diener HC, Jansen JP, Reches A, Pascual J, Pitel D, Steiner TJ. Efficacy, Tolerability and Safety of Oral Eletriptan and Ergotamine plus Caffeine (Cafergot((R)) in the Acute Treatment of Migraine: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Comparison. Eur Neurol 2002; 47: 99-107
11. Diener C. Flunarizine for migraine prophylaxis In: Diener HC (Ed.) Drug treatment of migraine and other headaches. Basel, Karger, 2000, 269-278
12. Diener HC, for the ASASUMAMIG Study Group. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study Cephalalgia 1999; 19, 581-588
13. Diener HC, for the RPR100893-201 Migraine Study Group. Substance P antagonist RPR100893-201 is not effective in human migraine attacks 6th International Headache Research Seminar, Copenhagen 1995, 245-371
14. Diener HC, Hartung E, Chrubasik J, Evers S, Schoenen J, Latta G, Gendolla A. on behalf of the Study Group Acetylsalicylic acid in migraine prophylaxis: a double blind study in comparison with metoprolol In "8th Congress of the International Headache Society, Amsterdam" 1997
15. Diener HC, Limmroth V. Advances in the pharmacological treatment of migraine. Exp Opinion Invest Drugs 2001; 10: 1831-1845
16. Dimitriadou V, Buzzi MG, Moskowitz MA, Theoharides TC. Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells. Neuroscience 1991; 44: 97-112
17. Edvinsson L, and Goadsby PJ. Neuro-peptides in migraine and cluster headache. Cephalalgia 1994; 14, 320-327
18. Edvinsson L, Goadsby PJ. Neuropeptides in headache. Eur J Neurol 1998, 5: 329-41
19. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358: 1668-75
20. Friberg L, Olesen J, Iversen HK, Sperling B. Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. Lancet 1991; 338: 13-7
21. Goadsby PJ, Edvinsson L. The trigemino-vascular system and migraine: studies characterizing cerebravascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993: 33, 48-56
22. Goadsby PJ, Zagami AS. Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat. Brain 1991; 114, 1001-1011
23. Goldstein DJ, Roon KI, Offen WW, Ramadan NM, Phebus LA, Johnson KW, Schaus JM, Ferrari MD. Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet 2001; 358: 1230-4
24. Goldstein DJ, Wang O, Saper JR, Stoltz R, Silberstein ST, and Mathew NT. Ineffectiveness of neurokinin-1 antagonist in acute migraine: crossover study. Cephalalgia 1997; 17, 785-790
25. Goldstein J, Ryan R, Jiang K, Getson A, Norman B, Block G, Lines C, and the Rizatriptan Protocol 046 Study Group. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 and 50 mg in migraine. Headache 1998; 38, 737-747
26. Gomez-Mancilla B, Cutler NR, Leibowitz MT, Spierings EL, Klapper JA, Diamond S, Goldstein J, Smith T, Couch JR, Fleishaker J, Azie N, Blunt DE. Safety and efficacy of PNU-142633, a selective 5-HT1 D agonist, in patients with acute migraine. Cephalalgia 2001; 21: 727-32
27. Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, Kwong KK, Cutrer FM, Rosen BR, Tootell RB, Sorensen AG, Moskowitz MA. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A 2001; 98: 4687-92
28. Jensen R, Brinck T, and Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study Neurology 1994; 44, 647-651
29. John GW, Pauwels PJ, Perez M, Halazy S, LeGrand B, Verscheure Y, Valentin JP, Palmier C, Wurch T, Chopin P, Marien M, Kleven MS, Koek W, Assie MB, Carilla-Durand E, Tarayre JP, Colpaert FCJ. F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1 D receptors in models relevant to migraine. Pharmacol Exp Ther 1999; 290: 83-95
30. Joutel A, Bousser, M, Biousese, V, Labauge, P, Chabriat, H, Nibbio, A, Maciazek, J, Meyer, B, Bach, M, Weissenbach, J, Lathrop, G M, and Tournier-Lasserve E. A gene for familial hemiplegic migraine maps to chromosome 19 Nature Genetics 1993; 5, 40-45
31. Kaube H, Herzog J, Kaufer T, Dichgans M, Diener HC. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology 2000; 55: 139-41
32. Klapper, J, on behalf of the Divalproex Sodium in Migraine Prophylaxis Study Group Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997; 17:103-108
33. Lampl C, Buzath A, Klinger D, Neumann K. Lamotrigine in the prophylactic treatment of migraine aura - a pilot study. Cephalalgia 1999; 19: 58-63
34. Limmroth V, May A, Auerbach P, Wosnitza G, Eppe T, Diener HC. Changes of cerebral blood flow velocity after treatment with sumatriptan or placebo and its implication in the pathophysiology of migraine. J Neurol Sci 1996; 138, 60-65
35. Limmroth V, Katsarava Z, Diener HC. Acetylsalicylic acid in the treatment of migraine and other headache - a historical and current overview. Cephalalgia 1999; 19: 545-551
36. Limmroth V, May A, Diener HC. Lysine-acetylsalicytic acid in acute migraine attacks. Eur Neurol 1999; 41, 88-93
37. Limmroth V, Michel MC. The Prevention of Migraine: a critical review with special emphasis on β-blockers. Br J Clin Pharmacol 2001; 52: 237-243
38. Limmroth V, Katsarava Z, Liedert, B, Schubert K, Michel M, Diener HC. A new in-vivo rat model for CGRP release following the activation of the trigeminal vascular system. Pain 2001; 92, 101-106
39. Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, Stacey B, Tepper S. Efficacy of gabapentin in migraine prophylaxis. Headache 2001; 4: 119-28
40. Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S, Rapoport AM, Silber CJ, and Deaton RL. Migraine prophylaxis with divalproex. Arch Neurol 1995; 52, 281-286
41. May A, Gijsman HJ, Wallnöfer A, Jones R, Diener HC, Ferrari MD Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 1996; 67, 375-378
42. May A, Kaube H, Buchel C, Eichten C, Rijntjes M, Juptner M, Weiller C, Diener HC. Experimental cranial pain elicited by capsaicin: a PET study. Pain 1998; 74: 61-6
43. Melchart D, Linde K, Fischer P, White A, Allais G, Vickers A, Berman B. Acupuncture for recurrent headaches: a systematic review of randomized controlled trials. Cephalalgia 1999; 19, 779-786
44. Moskowitz MA. Basic mechanisms in vascular headache. Neurologic Clinics 1990; 8, 801-815
45. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. TiPS 1992; 13, 307-311
46. Myllyla VV, Havanka H, Herrala L, Kangasniemi P, Rautakorpi I, Turkka J, Vapaatalo H, Eskerod O. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: Comparable effect in a double-blind, randomized, controlled, parallel-group study. Headache 1998; 38, 201-207
47. Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SMG, Lamerdin JE, Mohrenweiser HW, Bulman DE, Ferrari M, Haan J, Lindhout D, van Ommen GB, Hofker MH, Ferrari MD, Frants RR. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1997; 87, 543-552
48. Roon K I, Olesen J, Diener HC, Ellis P, Hettiarachchi J, Poole PH, Christianssen I, Kleinermans D, Kok JG, Ferrari MD. No acute antimigraine efficiacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials. Ann Neurol 2000; 47, 238-241
49. Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997; 17: 109-12
50. Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 2001; 41: 968-75
51. Tfelt-Hansen P, Henry P, Mulder LJ, Schaeldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995; 346, 923-926
52. Tfelt-Hansen P, Teall J, Rodriguez F, Giacovazzo M, Paz J, Malbecq W, Block GA, Reines SA, Visser WH. on behalf of the Rizatriptan 030 Study Group Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine Headache 1998; 38, 748-755
53. The Diclofenac-K/Sumatriptan Migraine Study Group. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal antiinflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. Cephalalgia 1999; 19, 232-240
54. Weiller C, May A, Limmroth V, Jüptner M, Kaube H, van Schayck R, Coenen HH, Diener HC. Brain stem activation in spontaneous human migraine attacks. Nature Medicine 1995; 1, 658-660